Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SunWay Biotech CoROCO:1271 -4.39%90 Piotroski F-Score is 6 as of Jul. 15, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates ROCO:1271 with a GF Score™ of 90/100 and a GF Value™ of NT$71.11 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,910 Consumer Packaged Goods companies, SunWay Biotech Co ranks better than 73.14% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
SunWay Biotech Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for SunWay Biotech Co's Piotroski F-Score or its related term are showing as below:
ROCO:1271'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 5 Max: 7
Current: 6
During the past 7 years, the highest Piotroski F-Score of SunWay Biotech Co was 7. The lowest was 4. And the median was 5.
SunWay Biotech Co (ROCO:1271) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
SunWay Biotech Co Piotroski F-Score Related Terms
SunWay Biotech Co Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for SunWay Biotech Co's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1271 vs KHC, GIS: Piotroski F-Score Comparison
For the Packaged Foods subindustry, SunWay Biotech Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SunWay Biotech Co Piotroski F-Score vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, SunWay Biotech Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where SunWay Biotech Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
SunWay Biotech Co's current Net Income (TTM) was 101.5.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
SunWay Biotech Co's return on assets of this year was 0.02676462. SunWay Biotech Co's return on assets of last year was 0.0317073.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
SunWay Biotech Co's gearing of this year was 0.15114853. SunWay Biotech Co's gearing of last year was 0.06026278.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
SunWay Biotech Co's current ratio of this year was 1.62447255. SunWay Biotech Co's current ratio of last year was 3.69442667.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
SunWay Biotech Co's number of shares in issue this year was 60.302. SunWay Biotech Co's number of shares in issue last year was 60.438.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
SunWay Biotech Co's gross margin of this year was 0.564283. SunWay Biotech Co's gross margin of last year was 0.56179117.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
SunWay Biotech Co's asset turnover of this year was 0.26191716. SunWay Biotech Co's asset turnover of last year was 0.25943528.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
1
+
0
+
0
+
1
+
1
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
SunWay Biotech Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.
SunWay Biotech Co (ROCO:1271) has a Piotroski F-Score of 6 as of Jul. 15, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on SunWay Biotech Co and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, SunWay Biotech Co's Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, SunWay Biotech Co ranks #513 out of 1910 companies in the Consumer Packaged Goods industry, placing it in the top 26.9%.
Is SunWay Biotech Co's Piotroski F-Score too high?
SunWay Biotech Co's current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Consumer Packaged Goods industry median Piotroski F-Score is 5.00. SunWay Biotech Co's value of 6 is 20% above this industry median. Based on the distribution chart, SunWay Biotech Co ranks #513 out of 1910 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, SunWay Biotech Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SunWay Biotech Co's Piotroski F-Score compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, SunWay Biotech Co ranks #513 out of 1910 companies for Piotroski F-Score. This puts SunWay Biotech Co in the upper half of its industry. The industry median Piotroski F-Score is 5.00. SunWay Biotech Co's value of 6 is 20% above this benchmark. Historically, SunWay Biotech Co's own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, SunWay Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Consumer Packaged Goods company?
The median Piotroski F-Score among Consumer Packaged Goods companies is 5.00, based on 1,910 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SunWay Biotech Co's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on SunWay Biotech Co and its competitors. For the Consumer Packaged Goods industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SunWay Biotech Co's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SunWay Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, SunWay Biotech Co (ROCO:1271) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$71.11, compared to a current price of NT$61.00 — trading 14.2% below its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 20% above the Consumer Packaged Goods industry median of 5.00. SunWay Biotech Co's overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For SunWay Biotech Co (ROCO:1271), the current Piotroski F-Score is 6 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SunWay Biotech Co (ROCO:1271) Overvalued in 2026?
Based on GuruFocus' analysis, SunWay Biotech Co stock appears to be undervalued.
The current stock price of NT$61.00 is trading 14.2% below its estimated GF Value™ of NT$71.11.
GuruFocus considers SunWay Biotech Co to be Modestly Undervalued.
Key valuation signals for ROCO:1271:
Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
GF Value™: NT$71.11 vs. price of NT$61.00 (14.2% below fair value)
Industry Position: 20% above the Consumer Packaged Goods median (#513 of 1910)
No single metric tells the full story. See the ROCO:1271 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SunWay Biotech Co Ltd is engaged in the research, design and manufacturing of Monascus purpureus NTU 568, Lactobacillus paracasei subsp, paracasei NTU 101, and the related products.
90GF Score
Get the complete analysis for ROCO:1271
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1271 has been successfully added to your 
